Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Limited
Filing Type: Form 8-K (Current Report)
Date of Report: May 28, 2025
Event: Entry into Material Definitive Agreements involving the issuance of senior notes by wholly-owned subsidiaries to fund a tender offer and repay outstanding debt.
Key Financial Metrics and Debt Issuance
The Company's subsidiaries issued a total of approximately €1.0 billion and $1.2 billion in senior notes on May 28, 2025. The specific terms are as follows:
- 2031 Euro Notes: €1,000,000,000 aggregate principal; 4.125% interest rate; matures June 1, 2031.
- 2032 USD Notes: $500,000,000 aggregate principal; 6.000% interest rate; matures December 1, 2032.
- 2030 USD Notes: $700,000,000 aggregate principal; 5.750% interest rate; matures December 1, 2030.
Use of Proceeds: Net proceeds are designated to fund an upsized tender offer with a maximum purchase price of up to $2,250,000,000 (increased from a previous cap of $2,000,000,000), pay associated fees, and repay outstanding debt upon maturity or redemption.
Material Changes and Debt Structure
This filing represents a significant increase in the Company's debt obligations to facilitate capital restructuring. The tender offer cap was increased by $250,000,000 compared to prior announcements. The new notes are senior unsecured obligations of the respective issuers and are guaranteed on a senior unsecured basis by Teva Pharmaceutical Industries Limited. Interest payments on the USD notes commence December 1, 2025, while Euro notes interest begins June 1, 2026.
Guidance, Risks, and Covenants
Covenants: The indentures limit the Company's ability to create liens on certain property, enter into sale-leaseback transactions, and restrict mergers, consolidations, or asset sales without compliance with specified exceptions.
Redemption Terms: The notes are redeemable at the issuer's option with 10 to 60 days' notice. Early redemption prices are generally the greater of 100% of principal or the present value of remaining payments plus accrued interest. Redemption at par (100% of principal) is permitted within three months of maturity.
Events of Default: Include nonpayment of principal or interest, breach of covenants, acceleration of other indebtedness, failure of the guarantee to be enforceable, and bankruptcy or insolvency events.
Investor Verification Checklist
- Verify the final acceptance rate and total cost of the tender offer for the $2.25 billion cap.
- Confirm the specific outstanding debt instruments targeted for repayment with the net proceeds.
- Review the impact of the new interest rates (4.125% - 6.000%) on the Company's future interest expense and EBITDA coverage ratios.
- Assess the Company's liquidity position post-issuance to ensure compliance with the new indenture covenants regarding liens and asset sales.